[New therapy approaches for giant cell tumors]

Area of Science:

• Orthopedics
• Oncology
• Pathology

Background:

• Giant cell bone tumors (GCTs) are benign, locally aggressive osteolytic tumors.
• Typically occurring around the knee, GCTs can cause bone destruction and rarely metastasize or become malignant.
• Previous classifications considered GCTs 'semimalignant' due to their aggressive behavior.

Purpose of the Study:

• To evaluate novel therapeutic strategies for Giant Cell Bone Tumors (GCTs).
• To explore the efficacy of RANKL inhibitors as an alternative treatment for GCTs.
• To provide insights into managing GCTs, particularly in cases with challenging localizations or recurrence.

Main Methods:

• Review of established surgical techniques including intralesional curettage and defect reconstruction with bone cement.
• Analysis of histological features of GCTs, focusing on osteoclastic giant cells and stromal cells.
• Investigation of novel pharmaceutical approaches targeting the receptor activator of nuclear factor-κB ligand (RANKL) pathway.

Main Results:

• Giant cell bone tumors exhibit high expression of RANKL, contributing to osteolytic activity.
• Novel therapies using monoclonal RANKL antibodies and bisphosphonates offer alternative treatment options.
• Denosumab, a monoclonal RANKL inhibitor, demonstrates efficacy in treating GCTs.

Conclusions:

• Denosumab represents a promising therapeutic alternative for GCT patients, particularly when surgical interventions have been unsatisfactory.
• Targeting the RANKL pathway provides a novel strategy for managing the osteolytic activity of GCTs.
• Further research into RANKL inhibition may lead to improved outcomes for GCT treatment.